Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Campbell McInnes

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunitCampbell McInnes, Martin J I Andrews, Daniella I Zheleva, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2002
Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal PheGail E Atkinson, Angela Cowan, Campbell McInnes, et al.
Cell Chemical Biology|July 19, 2018
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1Russell J Pearson, David G Blake, Mokdad Mezna, et al.
Chemmedchem|April 2, 2020
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor SuppressorMerissa Baxter, Danda Chapagai, Sandra Craig, et al.
Journal of Molecular Biology|June 15, 2005
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-bindingStanislava Uhrinova, Dusan Uhrin, Helen Powers, et al.
Organic & Biomolecular Chemistry|September 30, 2004
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexesMartin J I Andrews, Campbell McInnes, George Kontopidis, et al.
Journal of Medicinal Chemistry|April 13, 2019
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK ActivationChad M Beneker, Magdalini Rovoli, George Kontopidis, et al.
Chemmedchem|May 28, 2009
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided designGeorge Kontopidis, Martin J Andrews, Campbell McInnes, et al.
Journal of Medicinal Chemistry|January 18, 2013
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assemblyShu Liu, Padmavathy Nandha Premnath, Joshua K Bolger, et al.
European Journal of Medicinal Chemistry|November 4, 2021
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACESandra N Craig, Merissa Baxter, Danda Chapagai, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunitCampbell McInnes, Martin J I Andrews, Daniella I Zheleva, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2002
Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal PheGail E Atkinson, Angela Cowan, Campbell McInnes, et al.
Cell Chemical Biology|July 19, 2018
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1Russell J Pearson, David G Blake, Mokdad Mezna, et al.
Chemmedchem|April 2, 2020
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor SuppressorMerissa Baxter, Danda Chapagai, Sandra Craig, et al.
Journal of Molecular Biology|June 15, 2005
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-bindingStanislava Uhrinova, Dusan Uhrin, Helen Powers, et al.
Organic & Biomolecular Chemistry|September 30, 2004
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexesMartin J I Andrews, Campbell McInnes, George Kontopidis, et al.
Journal of Medicinal Chemistry|April 13, 2019
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK ActivationChad M Beneker, Magdalini Rovoli, George Kontopidis, et al.
Chemmedchem|May 28, 2009
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided designGeorge Kontopidis, Martin J Andrews, Campbell McInnes, et al.
Journal of Medicinal Chemistry|January 18, 2013
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assemblyShu Liu, Padmavathy Nandha Premnath, Joshua K Bolger, et al.
European Journal of Medicinal Chemistry|November 4, 2021
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACESandra N Craig, Merissa Baxter, Danda Chapagai, et al.
Pageof 7